Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and ...

The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

Advances in breast cancer diagnosis and treatment in the last 70 years have considerably increased the survival rate to 18.7 ...

On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...

EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...

Novartis on Friday announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

In the last four days, Divi's Lab share price has surged 13 per cent after global brokerage firm Citi initiated coverage on ...

The World Health Organization (WHO) reports that approximately 2,000 women are diagnosed with cancer each day. Every day, a ...

While supply chain diversification and the US Biosecure Act can help Divi's target the $800 million revenue opportunity from ...

Divi’s Laboratories share price rose 12.02% this week, driven by Citi Research’s ’buy’ rating and a target price of ₹6,400.

The FDA also approved a ribociclib and letrozole co-pack for the same indication Atezolizumab and hyaluronidase-tqjs for subcutaneous injection, for all adult indications, as the intravenous ...